Market Place
Sourcing Support
Moleculin Receives IRB Approval for MIRACLE Phase 3 AML Trial
12 Nov 2024 //
PR NEWSWIRE
Moleculin Announces Additional Positive AML Trial Data
14 Jun 2024 //
PR NEWSWIRE
Moleculin Announces Positive Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 2024 //
PR NEWSWIRE
Venus Remedies secures marketing approval for two oncology drugs
30 Dec 2023 //
INDIAN PHARMA POST
Moleculin Doses First Subjects in Phase 2 Portion of Trial Evaluating Annamycin
02 Oct 2023 //
PR NEWSWIRE
Japan`s Daiichi Sankyo gets US FDA nod for blood cancer treatment
21 Jul 2023 //
PRESS RELEASE
Nkarta`s cell therapy needs specific pre-conditioning
27 Jun 2023 //
FIERCE BIOTECH
Foghorn Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286
06 Jun 2023 //
GLOBENEWSWIRE
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline
27 Apr 2023 //
PR NEWSWIRE
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML
20 Apr 2023 //
BUSINESSWIRE
Jazz Pharma Secures Eight Additional Provincial Reimbursements for Vyxeos
08 Mar 2023 //
PRESS RELEASE
Italy grants clearance for Moleculin’s Phase I/II leukaemia therapy trial
22 Dec 2022 //
CLINICALTRIALSARENA
Quizartinib Granted Priority Review in the U.S. for Patients
24 Oct 2022 //
BUSINESSWIRE
Quizartinib MAA Validated by EMA for FLT3-ITD Positive AML
23 Aug 2022 //
BUSINESSWIRE
Hong Kong`s Generic Cytarabine Receives Approval in the U.S.
28 Feb 2022 //
FDA
Actinium Shows 72% MRD Negativity Rate in Phase 1 Study of Actimab-A + CLAG-M
14 Dec 2021 //
PRNEWSWIRE
BDR launches India’s first generic Midostaurin (MSTARIN) to treat Leukemia
07 Dec 2021 //
EXPRESS PHARMA
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study
11 Jun 2021 //
PRNEWSWIRE
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study
11 Jun 2021 //
PRNEWSWIRE
Oncopeptides presents new clinical & preclinical melflufen data at EHA meeting
12 May 2021 //
PRNEWSWIRE
Jazz Announces FDA Approval of Additional Indication for Vyxeos®
30 Mar 2021 //
PRNEWSWIRE
Gland Pharma`s Generic Cytarabine Receives Approval in US
27 Dec 2019 //
FDA
Ocuphire`s Announces Results from Two Ph2 Clinical Studies of Nyxol® Eye Drops
07 Nov 2019 //
BUSINESSWIRE
Regeneron, ArQule track progress on response rates
17 Jun 2019 //
ENDPTS
Biosight Receives Orphan Drug Designation From the FDA for BST-236
05 Jun 2019 //
PR NEWSWIRE
Decitabine Plus Chemo Denotes New Induction Therapy Option for AML
17 Mar 2019 //
ONCNET
Pfizer Receives FDA Approval For AML Drug
28 Nov 2018 //
SEEKING ALPHA
Final NICE green light for Pfizer’s Mylotarg
15 Nov 2018 //
PHARMA TIMES
NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML
10 Nov 2018 //
PHARMACEUTICAL TECH
NICE recommends Vyxeos for specific secondary AML
08 Nov 2018 //
BIOSPECTRUM
Jazz Pharms` Vyxeos (daunorubicin / cytarabine) Receives Approval in Europe
30 Oct 2018 //
EMA
Vyxeos® Receives Marketing Authorisation in the European Union for AML
27 Aug 2018 //
PR NEWSWIRE
Jazz hiring 100-plus sales reps for new narcolepsy and AML launches
20 Aug 2018 //
FIERCE PHARMA
Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for AML
01 Aug 2018 //
ENDPTS
Journal of Clinical Oncology publishes pivotal Ph3 data for Jazz Pharms` Vyxeos
19 Jul 2018 //
PR NEWSWIRE
CAR-T therapies leap towards EU approval
02 Jul 2018 //
PHARMATIMES
European Regulators Make Decisions on Several Companies’ Drugs
26 Feb 2018 //
BIOSPACE
National Comprehensive Cancer Network® adds Jazz Pharmaceuticals` Vyxeos™
08 Feb 2018 //
PR NEWSWIRE
Sagent Pharm’s Generic Cytarabine Receives Approval In US
14 Nov 2017 //
FDA
Speedy review for Jazz’ high-risk AML chemo
06 Nov 2017 //
PHARMA TIMES
FDA panel backs Pfizer`s once-pulled AML med Mylotarg
11 Jul 2017 //
FIERCE PHARMA
Pacira to stop making DepoCyt due to long-term production problems
06 Jul 2017 //
IN PHARMATECHNOLOGIST
Jazz Announces FDA Acceptance of NDA for VYXEOS™
31 May 2017 //
PR NEWSWIRE
Diplomat Now Dispensing RYDAPT® (Midostaurin) for Acute Myeloid Leukemia
18 May 2017 //
PR NEWSWIRE
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection
19 Sep 2016 //
EDQM
Celator Pharmaceuticals Presented PIII Trial Results in Acute Myeloid Leukemia
06 Jun 2016 //
PR NEWSWIRE
Celator® Pharma Announces Positive Data for VYXEOS™ in FLT3-ITD Mutated AML
18 Apr 2016 //
PR NEWSWIRE
Celator Announces Ph3 Trial for VYXEOS™in Patients with High-Risk Acute Leukemia
14 Mar 2016 //
PR NEWSWIRE
Celator Announces Participation in Cardiff University Clinical Trial in Adults
11 Jan 2016 //
PR NEWS WIRE
Mylan expands recalls from plants spanked in FDA warning letter
20 Aug 2015 //
FIERCE PHARMA MANUFACTURING
TaiGen initiates clinical trial of leukemia drug in China
04 May 2015 //
BIOSPECTRUM ASIA
India trouble. Four Different Cancer Drugs Recalled by Mylan
25 Apr 2015 //
FDA
